| Autor: |
Cereda, Cíntia Maria Saia, Mecatti, Daniel Sebbe, Papini, Juliana Zampoli Boava, Bueno, Diego Valério, Franz-Montan, Michelle, Rocha, Thalita, Júnior, José Pedrazzoli, Paula, Eneida de, Araújo, Daniele Ribeiro de, Grillo, Renato, Fraceto, Leonardo Fernandes, Calafatti, Silvana Aparecida, Tofoli, Giovana Radomille |
| Předmět: |
|
| Zdroj: |
Journal of Pain Research; Apr2018, Vol. 11, p683-691, 8p, 1 Color Photograph, 3 Charts, 2 Graphs |
| Abstrakt: |
Objective: This study reports a preclinical evaluation of an alginate/chitosan nanoparticle formulation containing NovaBupi®, a racemic bupivacaine (BVC) containing 25% dextrobupivacaine and 75% levobupivacaine. Methods: New Zealand White rabbits (n=6) received intraoral or intrathecal injections of BVC 0.5% or BVC 0.5%-loaded alginate–chitosan nanoparticles (BVCALG). BVC plasma levels and pharmacokinetic parameters were determined in blood samples of these rabbits. An infraorbital nerve blockade was performed in male Wistar rats (n=7) with the same formulations and the vehicle (NPALG). Histological evaluation of local toxicity after 6 hours and 24 hours of the treatments was performed in rats’ (n=6) oral tissues. Results: No statistically significant difference was observed between plasma concentrations and pharmacokinetic parameters (p>0.05) after intraoral injections. However, after intrathecal injection BVCALG changed approximately three times the values of volume of distribution and area under the curve (AUC0–t; p<0.05). The total analgesic effect of BVC after infraorbital nerve blockade was improved by 1.4-fold (p<0.001) with BVCALG. BVC and BVCALG did not induce significant local inflammatory reaction. Conclusion: The encapsulation of BVC prolongs the local anesthetic effect after infraorbital nerve blockade and altered the pharmacokinetics after intrathecal injection. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
